Avicanna (TSE:AVCN) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Avicanna has successfully completed its first delivery of proprietary topical products to a multinational pharmaceutical company, marking a significant step in its European commercial expansion. The products, which include CBD and CBG-based formulations, are set to launch in six European countries in 2025, leveraging the pharmaceutical company’s established infrastructure.
For further insights into TSE:AVCN stock, check out TipRanks’ Stock Analysis page.
